Quantitative profiling of protein tyrosine Kinases in human cancer cell lines by multiplexed parallel reaction monitoring assays

Molecular and Cellular Proteomics

Volumn 15, Issue 2, 2016, Pages 682-691

  Kim, Hye Jung ^a   Lin, De ^a   Lee, Hyoung Joo ^a   Li, Ming ^a   Liebler, Daniel C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; ERLOTINIB; PEPTIDE; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; PROTEOME; TUMOR PROTEIN;

ARTICLE; ASSAY; CANCER CELL LINE; CELL PROLIFERATION; COLON TUMOR; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; DOWN REGULATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG CANCER CELL LINE; LUNG TUMOR; MULTIPLEXED PARALLEL REACTION MONITORING ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; UPREGULATION; BIOSYNTHESIS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN-TYROSINE KINASES; PROTEOME;

EID: 84957926981     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.O115.056713     Document Type: Article

References (43)

1. Lemmon, M. A., and Schlessinger, J. (2010) Cell signaling by receptor tyrosine kinases. Cell 141, 1117-1134
2. Robinson, D. R., Wu, Y. M., and Lin, S. F. (2000) The protein tyrosine kinase family of the human genome. Oncogene 19, 5548-5557
3. Hubbard, S. R., and Till, J. H. (2000) Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 69, 373-398
4. Blume-Jensen, P., and Hunter, T. (2001) Oncogenic kinase signalling. Nature 411, 355-365
5. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298, 1912-1934
6. Zhang, J., Yang, P. L., and Gray, N. S. (2009) Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28-39
7. Liebler, D. C., and Zimmerman, L. J. (2013) Targeted quantitation of proteins by mass spectrometry. Biochemistry 52, 3797-3806
8. Addona, T. A., Abbatiello, S. E., Schilling, B., Skates, S. J., Mani, D. R., Bunk, D. M., Spiegelman, C. H., Zimmerman, L. J., Ham, A. J., Keshishian, H., Hall, S. C., Allen, S., Blackman, R. K., Borchers, C. H., Buck, C., Cardasis, H. L., Cusack, M. P., Dodder, N. G., Gibson, B. W., Held, J. M., Hiltke, T., Jackson, A., Johansen, E. B., Kinsinger, C. R., Li, J., Mesri, M., Neubert, T. A., Niles, R. K., Pulsipher, T. C., Ransohoff, D., Rodriguez, H., Rudnick, P. A., Smith, D., Tabb, D. L., Tegeler, T. J., Variyath, A. M., Vega-Montoto, L. J., Wahlander, A., Waldemarson, S., Wang, M., Whiteaker, J. R., Zhao, L., Anderson, N. L., Fisher, S. J., Liebler, D. C., Paulovich, A. G., Regnier, F. E., Tempst, P., and Carr, S. A. (2009) Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 27, 633-641
9. Barr, J. R., Maggio, V. L., Patterson, D. G., Jr., Cooper, G. R., Henderson, L. O., Turner, W. E., Smith, S. J., Hannon, W. H., Needham, L. L., and Sampson, E. J. (1996) Isotope dilution-mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Clin. Chem. 42, 1676-1682
10. Kuzyk, M. A., Smith, D., Yang, J., Cross, T. J., Jackson, A. M., Hardie, D. B., Anderson, N. L., and Borchers, C. H. (2009) Multiple reaction monitoringbased, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol. Cell. Proteomics 8, 1860-1877
11. Picotti, P., Bodenmiller, B., Mueller, L. N., Domon, B., and Aebersold, R. (2009) Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell 138, 795-806
12. Gallien, S., Duriez, E., Demeure, K., and Domon, B. (2013) Selectivity of LC-MS/MS analysis: implication for proteomics experiments. J. Proteomics 81, 148-158
13. Karlsson, C., Malmstrom, L., Aebersold, R., and Malmstrom, J. (2012) Proteome-wide selected reaction monitoring assays for the human pathogen Streptococcus pyogenes. Nat. Commun. 3, 1301
14. Gallien, S., Duriez, E., Crone, C., Kellmann, M., Moehring, T., and Domon, B. (2012) Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. Mol. Cell. Proteomics 11, 1709-1723
15. Peterson, A. C., Russell, J. D., Bailey, D. J., Westphall, M. S., and Coon, J. J. (2012) Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol. Cell. Proteomics 11, 1475-1488
16. Chen, Y., Gruidl, M., Remily-Wood, E., Liu, R. Z., Eschrich, S., Lloyd, M., Nasir, A., Bui, M. M., Huang, E., Shibata, D., Yeatman, T., and Koomen, J. M. (2010) Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry. J. Proteome Res. 9, 4215-4227
17. Rebecca, V. W., Wood, E., Fedorenko, I. V., Paraiso, K. H., Haarberg, H. E., Chen, Y., Xiang, Y., Sarnaik, A., Gibney, G. T., Sondak, V. K., Koomen, J. M., and Smalley, K. S. (2014) Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Mol. Cell. Proteomics 13, 1844-1854
18. Wolf-Yadlin, A., Hautaniemi, S., Lauffenburger, D. A., and White, F. M. (2007) Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc. Natl. Acad. Sci. U.S.A. 104, 5860-5865
19. Drabovich, A. P., Pavlou, M. P., Dimitromanolakis, A., and Diamandis, E. P. (2012) Quantitative analysis of energy metabolic pathways in MCF-7 breast cancer cells by selected reaction monitoring assay. Mol. Cell. Proteomics 11, 422-434
20. Ohashi, K., Sequist, L. V., Arcila, M. E., Moran, T., Chmielecki, J., Lin, Y. L., Pan, Y., Wang, L., de Stanchina, E., Shien, K., Aoe, K., Toyooka, S., Kiura, K., Fernandez-Cuesta, L., Fidias, P., Yang, J. C., Miller, V. A., Riely, G. J., Kris, M. G., Engelman, J. A., Vnencak-Jones, C. L., Dias-Santagata, D., Ladanyi, M., and Pao, W. (2012) Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc. Natl. Acad. Sci. U.S.A. 109, E2127-2133
21. Halvey, P. J., Wang, X., Wang, J., Bhat, A. A., Dhawan, P., Li, M., Zhang, B., Liebler, D. C., and Slebos, R. J. (2014) Proteogenomic analysis reveals unanticipated adaptations of colorectal tumor cells to deficiencies in DNA mismatch repair. Cancer Res. 74, 387-397
22. Sprung, R. W., Martinez, M. A., Carpenter, K. L., Ham, A. J., Washington, M. K., Arteaga, C. L., Sanders, M. E., and Liebler, D. C. (2012) Precision of multiple reaction monitoring mass spectrometry analysis of formalinfixed, paraffin-embedded tissue. J. Proteome Res. 11, 3498-3505
23. MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M., Finney, G. L., Frewen, B., Kern, R., Tabb, D. L., Liebler, D. C., and MacCoss, M. J. (2010) Skyline: An open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966-968
24. Zhang, H., Liu, Q., Zimmerman, L. J., Ham, A. J., Slebos, R. J., Rahman, J., Kikuchi, T., Massion, P. P., Carbone, D. P., Billheimer, D., and Liebler, D. C. (2011) Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry. Mol. Cell. Proteomics 10, M110 006593
25. Johnson, H., Lescarbeau, R. S., Gutierrez, J. A., and White, F. M. (2013) Phosphotyrosine profiling of NSCLC cells in response to EGF and HGF reveals network specific mediators of invasion. J. Proteome Res. 12, 1856-1867
26. Zhang, Y., Wolf-Yadlin, A., Ross, P. L., Pappin, D. J., Rush, J., Lauffenburger, D. A., and White, F. M. (2005) Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol. Cell. Proteomics 4, 1240-1250
27. Liu, Q., Ullery, J., Zhu, J., Liebler, D. C., Marnett, L. J., and Zhang, B. (2013) RNA-seq data analysis at the gene and CDS levels provides a comprehensive view of transcriptome responses induced by 4-hydroxynonenal. Mol. BioSyst. 9, 3036-3046
28. Trapnell, C., Hendrickson, D. G., Sauvageau, M., Goff, L., Rinn, J. L., and Pachter, L. (2013) Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat. Biotechnol. 31, 46-53
29. Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., and Pachter, L. (2012) Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protocols 7, 562-578
30. Halvey, P. J., Zhang, B., Coffey, R. J., Liebler, D. C., and Slebos, R. J. (2012) Proteomic consequences of a single gene mutation in a colorectal cancer model. J. Proteome Res. 11, 1184-1195
31. Myers, M. V., Manning, H. C., Coffey, R. J., and Liebler, D. C. (2012) Protein expression signatures for inhibition of epidermal growth factor receptormediated signaling. Mol. Cell. Proteomics 11, M111 015222
32. Waterman, H., and Yarden, Y. (2001) Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett. 490, 142-152
33. Fearon, E. R. (2011) Molecular genetics of colorectal cancer. Ann. Rev. Pathol. Mech. Dis. 6, 479-507
34. Hayes, T. K., and Der, C. J. (2013) Mutant and wild-Type Ras: co-conspir-Ators in cancer. Cancer Discov. 3, 24-26
35. Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., Ince, W. L., Janne, P. A., Januario, T., Johnson, D. H., Klein, P., Miller, V. A., Ostland, M. A., Ramies, D. A., Sebisanovic, D., Stinson, J. A., Zhang, Y. R., Seshagiri, S., and Hillan, K. J. (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900-5909
36. Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., and Varmus, H. E. (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, e17
37. Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C. M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C., and Janne, P. A. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043
38. Goldman, J. W., Laux, I., Chai, F., Savage, R. E., Ferrari, D., Garmey, E. G., Just, R. G., and Rosen, L. S. (2012) Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer 118, 5903-5911
39. Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., Apicella, M., Migliardi, G., Galimi, F., Lauricella, C., Zanon, C., Perera, T., Veronese, S., Corti, G., Amatu, A., Gambacorta, M., Diaz, L. A., Jr., Sausen, M., Velculescu, V. E., Comoglio, P., Trusolino, L., Di Nicolantonio, F., Giordano, S., and Siena, S. (2013) Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3, 658-673
40. Gallien, S., Kim, S. Y., and Domon, B. (2015) Large-Scale Targeted Proteomics Using Internal Standard Triggered-Parallel Reaction Monitoring (IS-PRM). Mol. Cell. Proteomics 14, 1630-1644
41. Shi, T., Fillmore, T. L., Sun, X., Zhao, R., Schepmoes, A. A., Hossain, M., Xie, F., Wu, S., Kim, J. S., Jones, N., Moore, R. J., Pasa-Tolic, L., Kagan, J., Rodland, K. D., Liu, T., Tang, K., Camp, D. G., 2nd, Smith, R. D., and Qian, W. J. (2012) Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc. Natl. Acad. Sci. U.S.A. 109, 15395-15400
42. Gajadhar, A. S., Johnson, H., Slebos, R. J., Shaddox, K., Wiles, K., Washington, M. K., Herline, A. J., Levine, D. A., Liebler, D. C., White, F. M., and Clinical Proteomic Tumor Analysis, C. (2015) Phosphotyrosine signaling analysis in human tumors is confounded by systemic ischemia-driven artifacts and intra-specimen heterogeneity. Cancer Res. 75, 1495-1503
43. Mertins, P., Yang, F., Liu, T., Mani, D. R., Petyuk, V. A., Gillette, M. A., Clauser, K. R., Qiao, J. W., Gritsenko, M. A., Moore, R. J., Levine, D. A., Townsend, R., Erdmann-Gilmore, P., Snider, J. E., Davies, S. R., Ruggles, K. V., Fenyo, D., Kitchens, R. T., Li, S., Olvera, N., Dao, F., Rodriguez, H., Chan, D. W., Liebler, D., White, F., Rodland, K. D., Mills, G. B., Smith, R. D., Paulovich, A. G., Ellis, M., and Carr, S. A. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol. Cell. Proteomics 13, 1690-1704